Elscint names Sardano to NM post
Israeli multimodality vendor Elscint has named Joe Sardano head of its U.S. nuclear medicine business unit, a position that previously had been vacant. Prior to joining Elscint in November, Sardano was with Fisher Scientific, and has also worked for
Israeli multimodality vendor Elscint has named Joe Sardano head of its U.S. nuclear medicine business unit, a position that previously had been vacant. Prior to joining Elscint in November, Sardano was with Fisher Scientific, and has also worked for Park, Toshiba, and Diasonics. Sardano said his priorities in the position are to expand Elscint's sales force, broaden the company's marketing efforts, and improve the vendor's customer satisfaction levels in the U.S.
Sardano will report to Eliezer Tokman, the Elscint CT veteran who was named to head the company's Americas regional operations in a restructuring announced in November (SCAN 11/12/97). Elscint is moving its global nuclear medicine headquarters to the U.S. as part of the restructuring.
Study with CT Data Suggests Women with PE Have More Than Triple the One-Year Mortality Rate than Men
April 3rd 2025After a multivariable assessment including age and comorbidities, women with pulmonary embolism (PE) had a 48 percent higher risk of one-year mortality than men with PE, according to a new study involving over 33,000 patients.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Predicting Diabetes on CT Scans: What New Research Reveals with Pancreatic Imaging Biomarkers
March 25th 2025Attenuation-based biomarkers on computed tomography (CT) scans demonstrated a 93 percent interclass correlation coefficient (ICC) agreement across three pancreatic segmentation algorithms for predicting diabetes, according to a study involving over 9,700 patients.
Can Photon-Counting CT be an Alternative to MRI for Assessing Liver Fat Fraction?
March 21st 2025Photon-counting CT fat fraction evaluation offered a maximum sensitivity of 81 percent for detecting steatosis and had a 91 percent ICC agreement with MRI proton density fat fraction assessment, according to new prospective research.
